Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ascendis Pharma A/S

174.13
+1.070.62%
Volume:207.73K
Turnover:36.13M
Market Cap:10.51B
PE:-27.67
High:177.06
Open:176.63
Low:172.00
Close:173.06
Loading ...

Ascendis Pharma Raised to Overweight From Equal-Weight by Morgan Stanley

Dow Jones
·
05 May

Stock Track | Ascendis Pharma Soars 7.44% Pre-Market on Strong Q1 Results and Analyst Upgrades

Stock Track
·
02 May

Ascendis Pharma Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
02 May

Ascendis Pharma a/S : Leerink Partners Raises Target Price to $200 From $190

THOMSON REUTERS
·
02 May

RBC Raises Price Target on Ascendis Pharma to $210 From $205, Keeps Outperform, Speculative Risk

MT Newswires Live
·
02 May

Ascendis Pharma AS (ASND) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...

GuruFocus.com
·
02 May

Ascendis Pharma A/S reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
02 May

Ascendis Pharma Q1 Loss Narrows, Revenue Rises

MT Newswires Live
·
02 May

Press Release: Ascendis Pharma Reports First Quarter 2025 Financial Results

Dow Jones
·
02 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
01 May

Ascendis Pharma A/S expected to post a loss of €1.47 a share - Earnings Preview

Reuters
·
30 Apr

Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025

GlobeNewswire
·
25 Apr

European Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading

MT Newswires Live
·
22 Apr

Ascendis Pharma down about 4% in morning trading

TIPRANKS
·
22 Apr

Ascendis Pharma (ASND) Gets a Buy from Bank of America Securities

TIPRANKS
·
17 Apr

Ascendis Pharma Initiated at Outperform by RBC Capital

Dow Jones
·
16 Apr

Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?

Zacks
·
16 Apr

Ascendis Pharma (ASND) Has a New Rating from RBC Capital

TIPRANKS
·
16 Apr

RBC Initiates Ascendis Pharma at Outperform, Speculative Risk With $205 Price Target

MT Newswires Live
·
16 Apr

Ascendis Pharma a/S : RBC Initiates Coverage With Outperform Rating; Price Target $205

THOMSON REUTERS
·
16 Apr